Overall Technical outlook

Price Summary

Jubilant Pharmova Limited's stock started trading at 1202.6 on 2025-07-16, climbed to 1204.7, fell to 1184.5, and closed -0.67% down at 1194.5, with 115146 shares traded.
The peak price for the stock in the past 52 weeks is 1254.55, with the lowest price being 722.9.

Technicals


Aroon: The AROON is currently in a neutral position for Jubilant Pharmova Limited, offering no clear guidance on whether the market is likely to move up or down. This neutral stance suggests that further observation may be necessary before a trend becomes apparent.
JUBLPHARMA aroon 99da47
Aroon chart for Jubilant Pharmova Limited


Bol. Bands: The BOLL BANDS is in a neutral stance, with no clear direction indicated for the market. This lack of clarity suggests that the market may be in a state of equilibrium for JUBLPHARMA, with no strong trend emerging.
JUBLPHARMA bbands 99da47
Bolinger Bands chart for Jubilant Pharmova Limited


Parabolic SAR: The PSAR maintains its bearish stance, setting a strong resistance level that could limit any potential upward movement. This ongoing bearish outlook suggests that the market may continue to face resistance, making it difficult to achieve significant gains for Jubilant Pharmova Limited.
JUBLPHARMA psar 99da47
Parabolic Stop and Reverse chart for Jubilant Pharmova Limited


Stochastic: The STOCHASTIC is showing a neutral stance, not indicating a clear upward or downward trend for Jubilant Pharmova Limited. This suggests a period of market balance, where neither side is showing dominance.
JUBLPHARMA stoch 99da47
Stochastic chart for Jubilant Pharmova Limited


Tripple Moving Agerage: The 20, 50, and 100 moving averages are aligned in a bearish formation, suggesting a downtrend. However, the slopes of the 20 and 50 SMAs are beginning to waver, indicating that the bearish momentum may be losing strength. This weakening could signal a potential shift towards bullish price action, as the market's current downward trajectory shows signs of faltering and a possible reversal may be near for JUBLPHARMA.
JUBLPHARMA trippleSMA 99da47
Tripple SMA chart for Jubilant Pharmova Limited


A thorough analysis of a company involves looking at both its fundamentals and technical data. The fundamentals, including revenue, profitability, and management quality, offer insight into the company's long-term value. Additionally, understanding the broader industry context, such as market competition and regulatory challenges, helps to better interpret the company's stock performance. By combining both fundamental and technical analysis, you can derive more meaningful inferences about the company's future prospects.